Skip to main content

SSRIs increase the risk of falls in patients with Dementia


January 19, 2012 - Nursing home residents with dementia who are selected using serotonin inhibitors reuptake (SSRIs), a decline that SSRIs, new research shows do not use the injury as compared withrisk is increased.In addition, the risk is dose dependent, average nonusers, authors, Rotterdam, Erasmus University Medical Centre, Netherlands, reported in S. Carolyn Sterke, MSc, lead 3 times the risk compared with those using food with.

 Carolyn Sterke
"Even at low doses, SSRIs in nursing home residents with dementia fall hazards are associated with a growing danger," the authors write.A hypnotic or sedative SSRI use with increased risk include even more.The study, published online January 18 in the British Journal of Clinical Pharmacology are.Vulnerable population"The poor are elderly patients," Josepha A. I Cheong, MD, University of Florida College of Medicine, Gainesville, Florida, who was not involved in the research professor of psychiatry, Medscape Medical News has reported.reaction or is likely to potentiate the side effects, including increased sedation, which may predispose a patient is definitely lacking, "he said.The study investigators analyzed the daily drug use and comes on every 2-year period, 248 nursing home residents with dementia January 1, 2006 January 1, 2008. The average age of participants was 82 years.Falls investigators SSRIs and antipsychotics, anxiolytics, hypnotics, sedatives, antidiabetic drugs, beta-blocker eyedrops, cardiovascular drugs, analgesics, anticholinergics, antihistamines, and antivertigo drug is known to increase risk, including other drugs and foods produced using , copies of medical records from the database.The most common SSRI citalopram, followed by paroxetine,,,, sertraline, and fluvoxamine was from. tricyclic antidepressants amitriptyline and nortriptyline were also used, including other antidepressants trazodone and mirtazapine.Need for new treatment protocolsDuring the study period, 152 residents (61.5%) had 683 falls. Thirty eight residents (15.4%) fell once, 114 (46.2%) fell often, authors are reported.Of falls (220 or 32.2%) resulted in a third of an injury. These falls, 10 (1.5%) resulted in a hip fracture, 11 injured in the (1.6%) were other fractures. One resident died as a result of a fall.Furthermore, the 198 falls (30.0%) injuries in other types of open wounds, sprains, bruises, swellings and other results.The study showed that the resulting reduction in the risk of injury increased with age (hazard ratio [HR], 1.05, 95% confidence interval [CI] 1.01 - 1.09), and use of antipsychotics (HR 1.76, 1.18 inCI 95% - 2,63).Increased risk of falls only SSRIs, was seen with the authors of the report. Overall, SSRIs associated with the use of HR 2.50 (- 4.19 95% CI, 1.50) did.The risk of dose dependence is seen with high doses of SSRI was with. Less than a quarter of defined daily doses, the risk increased 31 percent, half the risk in defined daily dose is increased by 73 percent and total daily dose, 198% increase risk (2.98 HR; 95 % CI, 1,94 - 4.57).The authors list several limitations of the study. The different characteristics of the patient, possible talks cytochrome P450, and other drug use, such as benzodiazepines, antihypertensives, and antipsychotics are, concomitantly SSRs with include.Caution when prescribingDevelopment should consider, "he said in a statement that Ms. Sterke."The reason that people fall more often when using these drugs, including SSRIs. Think," he told Medscape Medical News."Central nervous system adverse effects have been other studies, such as daytime drowsiness, sedation, dizziness, extrapyramidal symptoms and Orthostatic hypotension and syncope, which affects the motor system is increased risk of falls with SSRI use To link has been proposed as possible explanations., "he said.Ms. Sterke also believe that doctors prescribe SSRIs to patients before they should be very careful.should be., he said. ""The study results of depression in nursing home professionals to help residents and residents with positive investment activities initiated and helped to demonstrate the least bit worried," he said."The authors take into account other drugs, but how do you say that the falls were due to SSRIs and other drugs can not," Dr. Cheong is the point."We already know that SSRIs and other medications to prevent drug metabolism in small quantities, or may be less than SSRIs authors also say that several factors may be responsible. Study if they had a strong age . nondemented people who were on the same drug combination, "he said.Dr Cheong also said that depression and dementia in nursing home patients, SSRIs may be wrong to prevent a major factor."The most clinicians approach patients on multiple medication regimen when adding an SSRI to monitor the alarm is due, he said.''

Labels:

Comments

Post a Comment

Popular posts from this blog

Antidepressants Linked to Higher Diabetes Risk in Kids

Pediatric patients who use antidepressants may have an elevated risk for type 2 diabetes, the authors of a new study report. In a retrospective cohort study of more than 119,000 youths 5 to 20 years of age, the risk for incident type 2 diabetes was nearly twice as high among current users of certain types of antidepressants as among former users, Mehmet Burcu, PhD, and colleagues report in an article  published online October 16 in  JAMA Pediatrics . The risk intensified with increasing duration of use, greater cumulative doses, and higher daily doses of these antidepressants. The findings point to a growing need for closer monitoring of these products, including greater balancing of risks and benefits, in the pediatric population, the authors caution. They undertook the study because, despite growing evidence of an association between antidepressant use and an increased risk for type 2 diabetes in adults, similar research in pediatric patients was scarce. "To our know...
Post a Comment
Read more

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...
Post a Comment
Read more

Missing Data Lead FDA Panel to Vote Against Rivaroxaban for ACS May 23, 2012 (Updated May 24, 2012) (Silver Spring, Maryland) — The missing data issues plaguing the ATLAS ACS 2 TIMI 51 trial of the factor Xa inhibitor rivaroxaban (Xarelto, Bayer Healthcare/Janssen Pharmaceuticals) have prevented the drug from earning the endorsement of the FDA Cardiovascular and Renal Drugs Advisory Committee. At its May 23 meeting, the panel voted six to four (with one abstention) against recommending that the FDA approve rivaroxaban for reducing the risk of thrombotic cardiovascular events in patients with acute coronary syndrome or unstable angina in combination with aspirin, aspirin plus clopidogrel, or ticlopidine. Janssen's application is based on the results of the ATLAS ACS 2 phase 3 and the ATLAS ACS TIMI 46 phase 2 trial. The placebo-controlled ATLAS ACS 2 showed rivaroxaban reduced the risk of both all-cause and cardiovascular mortality while increasing the risk of bleeding and intracranial hemorrhage, but the studies were hindered by early patient withdrawals and missing data. We Don't Know What We're Missing Based on the ATLAS ACS 2 results, FDA reviewer Dr Karen Hicks recommended approval of rivaroxaban for the requested indications except all-cause mortality. However, another FDA reviewer, Dr Thomas Marciniak, was adamant that the trial results are not interpretable because about 12% of the patients had incomplete follow-up, far higher than the 1% to 1.5% differences in the end-point rates between rivaroxaban and placebo. A total of 1294 subjects discontinued the trial prematurely, and the company was only able to contact 183, of which 177 were confirmed to be alive. Because of the patient dropouts, the company adopted a "modified intention-to-treat analysis," whereby patients were observed for 30 days after randomization or the global end date for the trial, instead of observing all the patients until the end of the trial as the FDA originally suggested. Marciniak criticized the sponsor's efforts to follow the patients and said that three patient deaths not counted in the modified intention-to-treat analysis may just be the "tip of the iceberg." Because the percentage of patients whose ultimate vital status remains unknown is much greater than the reported differences in mortality rates, the claimed mortality benefits are not reliable. The majority of the panel sided with Marciniak. For example, Dr Sanjay Kaul (University of California, Los Angeles) voted "no" because "there was enough uncertainty in the quality and robustness of the data that dissuaded me from voting yes. . . . The 'missingness' of the data doesn't invalidate it, but it certainly makes it hard to infer [the conclusion]." Dr Steven Nissen (Cleveland Clinic, OH) said that the decision to use the modified intention-to-treat analysis had a "profound impact" on the interpretability of the data. "It's saying we don't care what happens after 30 days, [and] that colored the trial in ways we couldn't recover from." Given the risk of major bleeding, "I want to see better evidence that this strategy of adding an Xa inhibitor or a direct thrombin inhibitor or something else to a good antiplatelet agent is robustly better for the patient," Nissen said. He recommends that the companies run a new trial of the 2.5 twice-daily dose of rivaroxaban using a strict intention-to-treat approach, but, he said, "I don't expect the death benefit to be too robust." Several panelists said they were concerned that the patients who dropped out of the trial were disproportionately likely to have a bleeding event, which led them to quit the trial, or a "protopathic" event, as statistician Dr Scott Emerson (University of Washington, Seattle) put it. "We're worried that an impending event is what is changing their behavior. We see that all the time in clinical trials--that regularly measured end points do not pick up [all of] the events," he said. He said that since the company was only able to contact 183 of the over 1200 patients who dropped out, it is possible that the dropouts skew the outcomes comparison of the trial. "Differential event rates after dropout are the number-one thing we're afraid of, so you have to explore it" in a statistical sensitivity analysis of the potential impact of these unknown outcomes. "It would not surprise me if, at the end of the day, these data did not hold up under a proper sensitivity analysis," he said. "What I want to know is, among the people who had events, how differential was the follow-up, but I can tell you by just looking at it, there was a very slightly different amount of follow-up of the people in the treatment arm. But I don't know whether everyone in the treatment arm was cured and they were trekking in the Himalayas and everyone in the placebo arm went home to die. I don't know that that's not the case." Dr Maury Krantz (University of Colorado, Denver) voted in favor of approval but said he does not know how rivaroxaban would perform in general clinical practice, especially when used with aspirin and clopidogrel. "I felt very much torn by this. This isn't a simple paradigm shift. It means going to triple therapy, which is really a three-headed monster in many ways. I think that what you're going to see in practice, if this is not done carefully with the proper labeling and secondary studies, is really dramatic magnification of bleeding and perhaps minimization of the efficacy benefit."

May 23, 2012   (Updated May 24, 2012)  (Silver Spring, Maryland)  —  The missing data issues plaguing the  ATLAS ACS 2 TIMI 51   trial of the factor Xa inhibitor  rivaroxaban  (Xarelto, Bayer Healthcare/Janssen Pharmaceuticals) have prevented the drug from earning the endorsement of the  FDA  Cardiovascular and Renal Drugs Advisory Committee. At its May 23 meeting , the panel voted six to four (with one abstention) against recommending that the FDA approve rivaroxaban for reducing the risk of thrombotic cardiovascular events in patients with acute coronary syndrome or unstable angina in combination with aspirin, aspirin plus  clopidogrel , or  ticlopidine . Janssen's application is based on the results of the ATLAS ACS 2 phase 3 and the  ATLAS ACS TIMI 46   phase 2 trial. The placebo-controlled ATLAS ACS 2 showed rivaroxaban reduced the risk of both all-cause and cardiovascular mortality while increasing the ri...
Post a Comment
Read more